Canadian Fabry Disease Initiative (CFDI) National Registry
NCT ID: NCT00455104
Last Updated: 2024-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2007-01-31
2029-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease, stroke and/or premature death; often before the age of 60.
Fabry Disease is estimated to affect approximately one out of every 40,000 males and up to twice as many females in Canada. We do not have the exact number of persons in Canada who have this disease. A common problem in studying rare conditions is the difficulty in identifying the majority of people suffering from such a disease. Gathering their health information in order to better understand the natural disease progression and its response to treatment is difficult.
Early ERT studies involving humans had small numbers of subjects and the studies were of short duration. The results of these clinical studies did lead to approval of the therapy in many countries around the world including Canada. To date though, evidence of the usefulness of ERT and its direct impact on the natural course of Fabry disease has been limited, while its cost continues to be very high. As a result of these issues, there will need to be continued and long-term collection of information related to the effectiveness of ERT and other treatments to better document its true clinical outcomes in Canadian people with Fabry disease.
The Canadian Fabry Disease Initiative National Registry (CFDI-NR) is an observational, voluntary registry designed to collect outcomes data on Fabry disease from people living in Canada.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fabry Screening Study
NCT01019629
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain
NCT02450604
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
NCT02009345
Early Detection of Fabry Disease
NCT05106764
The Genetic Basis of Acquired Heart Disease in Africa
NCT02124109
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are over 600 people in Canada known to have Fabry Disease. For more details about Fabry Disease, please refer to the "Brief Summary."
The goals of this nation-wide study are as follows:
1. To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada;
2. To determine clinical outcomes of patients with Fabry disease including those on treatment;
3. To determine if urine and plasma Gb3 and globotriasylsphingosine (LysoGb3) and their analogues can be biomarkers for Fabry disease and can predict clinical outcomes.
Data will be collected at baseline and every 12 months, as follows:
* Medical History
* Physical examination
* Neurological exam
* Electrocardiogram (ECG) - an electrical tracing of one's heart rhythm
* Echocardiogram (ultrasound of the heart)
* Holter monitor
* Magnetic Resonance Imaging (MRI) or CT Scan of the head
* Lab tests (including alpha-galactosidase levels)
* Review of current medications
* 24-hour urine collection or a random spot urine test
* Biomarker samples
To date though, evidence of the usefulness of ERT and its direct impact on the natural course of Fabry disease has been limited, while its cost continues to be very high (approximately $300,000 CDN per year per patient). As a result of these issues, there will need to be continued and long-term collection of information related to the effectiveness of ERT and other treatments to better document its true clinical outcomes in Canadian people with Fabry disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
National Registry
To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
No intervention
This is an observational, voluntary registry.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
This is an observational, voluntary registry.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give informed consent; and
* A clinical diagnosis of Fabry disease; and
* Compliance with all the clinic visits, interviews and assessments during the study period; and
* A Canadian citizen or a landed immigrant
Exclusion Criteria
* Problem complying with all the clinic visits, interviews and assessments during the study period; or
* An estimated life expectancy of less than 12 months
* Under 5 years of age
* Non-disease causing mutation
5 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nova Scotia Health Authority
OTHER
Canadian Fabry Research Consortium
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael L West, MD
Role: PRINCIPAL_INVESTIGATOR
Queen Elizabeth II Health Sciences Centre (Capital District Health Authority), Halifax, Nova Scotia, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alberta Children's Hospital
Calgary, Alberta, Canada
Vancouver General Hospital Adult Metabolic Diseases Clinic
Vancouver, British Columbia, Canada
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
University of Montreal, Department of Medicine
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Fabry Disease: recommendations for diagnosis, management, and enzyme replacement therapy in Canada Nov 2005
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFDI 001 - NR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.